Skip to Main Content

Author Details

Yoke-Eng Chiew
Westmead Hospital
1987
26
20
PMIDPaper TitleJournal TitlePublished Year
34697060DNA Methylation Profiles of Ovarian Clear Cell Carcinoma.Cancer Epidemiol Biomarkers Prev2022
35816189Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes.Clin Cancer Res2022
36456881The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.Nat Genet2022
32554541Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).Clin Cancer Res2020
29061645Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.Clin Cancer Res2018
35135122<i>BRAF</i> Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition.JCO Precis Oncol2018
29367611Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer.Sci Rep2018
28646021<i>EIF1AX</i> and <i>NRAS</i> Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas.Cancer Res2017
28346442Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.Nat Genet2017
26017449Whole-genome characterization of chemoresistant ovarian cancer.Nature2015
26506417Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.Oncotarget2015
26503049Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.Nature2015
26152742Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium.Clin Cancer Res2015
25316818Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.Clin Cancer Res2014
21976534Copy number aberrations in benign serous ovarian tumors: a case for reclassification?Clin Cancer Res2011
19193619Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.Clin Cancer Res2009
18698038Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.Clin Cancer Res2008
18980987Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.Clin Cancer Res2008
17344846Patterns of somatic mutation in human cancer genomes.Nature2007
16213010MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma.Gynecol Oncol2006
15986428Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer.Int J Cancer2005
11106251Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells.Clin Cancer Res2000
10918187Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines.Int J Cancer2000
9269899Antisense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells.Cell Growth Differ1997
1517234Effect of sodium butyrate on estrogen receptor and epidermal growth factor receptor gene expression in human breast cancer cell lines.J Biol Chem1992
2825791Studies on pig liver mevalonate-5-diphosphate decarboxylase.Biochim Biophys Acta1987
  • 1 - 26 of 26

Recommended Authors

British Columbia Women's Hospital and Health Centre
Career Start Year 2004
Number of shared co-authors 36
National Cancer Institute, National Institutes of Health
Career Start Year 2002
Number of shared co-authors 1
UCD Conway Institute, University College Dublin
Career Start Year 2001
Number of shared co-authors 0
Mayo Clinic
Career Start Year 2001
Number of shared co-authors 23
University of British Columbia
Career Start Year 2000
Number of shared co-authors 28
Uppsala University
Career Start Year 1999
Number of shared co-authors 0
Karolinska Institutet
Career Start Year 1997
Number of shared co-authors 3
The University of Texas MD Anderson Cancer Center
Career Start Year 1996
Number of shared co-authors 0
University of British Columbia
Career Start Year 1993
Number of shared co-authors 29
Radboud University Medical Center
Career Start Year 1993
Number of shared co-authors 12
University of South Carolina
Career Start Year 1993
Number of shared co-authors 0
University of Edinburgh
Career Start Year 1992
Number of shared co-authors 11
Oncology R&D
Career Start Year 1992
Number of shared co-authors 5
Cancer Research UK Cambridge Institute, University of Cambridge
Career Start Year 1992
Number of shared co-authors 65
The University of Texas MD Anderson Cancer Center, UT MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 4
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 34
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 4
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Career Start Year 1990
Number of shared co-authors 57
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 5
Department of Pharmaceutical Chemistry, University of California san francisco
Career Start Year 1987
Number of shared co-authors 0
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Career Start Year 1986
Number of shared co-authors 0
Karolinska Institute
Career Start Year 1984
Number of shared co-authors 11
Dana-Farber Cancer Institute
Career Start Year 1984
Number of shared co-authors 9
Mayo Clinic Jacksonville
Career Start Year 1982
Number of shared co-authors 6
UCSF Helen Diller Family Comprehensive Cancer Center
Career Start Year 1982
Number of shared co-authors 88
USA The Jackson Laboratory Cancer Center
Career Start Year 1982
Number of shared co-authors 7
Buck Institute for Research on Aging
Career Start Year 1977
Number of shared co-authors 5
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 40
Foundation Medicine
Career Start Year 1974
Number of shared co-authors 4
University of Alabama at Birmingham
Career Start Year 1974
Number of shared co-authors 2

Collaborators

Westmead Hospital
Co-authored papers 25
The Westmead Institute for Medical Research, University of Sydney
Co-authored papers 15
Westmead Clinical School, University of Sydney
Co-authored papers 12
Peter MacCallum Cancer Centre
Co-authored papers 11
Peter MacCallum Cancer Centre
Co-authored papers 10
Peter MacCallum Cancer Centre
Co-authored papers 8
Peter MacCallum Cancer Centre
Co-authored papers 8
Peter MacCallum Cancer Centre
Co-authored papers 7
Westmead Hospital
Co-authored papers 7
Westmead Hospital
Co-authored papers 7
Peter MacCallum Cancer Centre
Co-authored papers 6
Mayo Clinic
Co-authored papers 6
University of British Columbia
Co-authored papers 6
David Geffen School of Medicine, University of California los angeles
Co-authored papers 6
Mayo Clinic College of Medicine
Co-authored papers 6
Westmead Institute for Medical Research, The University of Sydney
Co-authored papers 6
The University of Melbourne
Co-authored papers 5
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 5
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 5
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 5
QIMR Berghofer Medical Research Institute
Co-authored papers 5
QIMR Berghofer Medical Research Institute
Co-authored papers 5
QIMR Berghofer Medical Research Institute
Co-authored papers 5
Peter MacCallum Cancer Centre
Co-authored papers 5
University of Calgary
Co-authored papers 5
Co-authored papers 5
David Geffen School of Medicine, University of California at Los Angeles
Co-authored papers 5
QIMR Berghofer Medical Research Institute
Co-authored papers 5
University of British Columbia
Co-authored papers 5
The University of Melbourne
Co-authored papers 4